This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Nov;59(11):1586-7.

doi: 10.1136/gut.2009.191015. Epub 2010 Aug 23.

Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease

PMID: 20732919
DOI: 10.1136/gut.2009.191015

Comment

Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease

James D Lewis. Gut. 2010 Nov.

. 2010 Nov;59(11):1586-7.

doi: 10.1136/gut.2009.191015. Epub 2010 Aug 23.

Author

PMID: 20732919
DOI: 10.1136/gut.2009.191015

No abstract available

PubMed Disclaimer

Comment on

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Fidder H, et al. Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2. Gut. 2009. PMID: 18832524

Similar articles

Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS, Huo D. Kirschner BS, et al. Gastroenterology. 2007 Mar;132(3):1167-70. doi: 10.1053/j.gastro.2007.01.063. Gastroenterology. 2007. PMID: 17383435 No abstract available.
Babesiosis in a patient on infliximab for Crohn's disease.
Cullen G, Sands BE, Yajnik V. Cullen G, et al. Inflamm Bowel Dis. 2010 Aug;16(8):1269-70. doi: 10.1002/ibd.21158. Inflamm Bowel Dis. 2010. PMID: 19885904 No abstract available.
Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease.
Diamanti A, Castro M, Papadatou B, Ferretti F, Gambarara M. Diamanti A, et al. J Pediatr. 2002 May;140(5):636-7; author reply 637. doi: 10.1067/mpd.2002.123992. J Pediatr. 2002. PMID: 12032538 No abstract available.
[Indications and results of infliximab in Crohn's disease].
Karoui S, Boubaker J, Filali A. Karoui S, et al. Tunis Med. 2004 Dec;82(12):1057-63. Tunis Med. 2004. PMID: 15822505 Review. French.
Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
Rampton DS. Rampton DS. Gut. 2005 Oct;54(10):1360-2. doi: 10.1136/gut.2005.076034. Epub 2005 Aug 19. Gut. 2005. PMID: 16113045 Free PMC article. Review. No abstract available.

See all similar articles

Cited by

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration. Haynes K, et al. Arthritis Rheum. 2013 Jan;65(1):48-58. doi: 10.1002/art.37740. Arthritis Rheum. 2013. PMID: 23055441 Free PMC article.
Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
Targownik LE, Suissa S. Targownik LE, et al. Am J Gastroenterol. 2015 Dec;110(12):1647-50. doi: 10.1038/ajg.2015.210. Epub 2015 Sep 1. Am J Gastroenterol. 2015. PMID: 26323186
Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method.
Choi YY, Lee JK, Kim HS, Kim DW, Kim HM, Kang DR. Choi YY, et al. Yonsei Med J. 2021 Nov;62(11):997-1004. doi: 10.3349/ymj.2021.62.11.997. Yonsei Med J. 2021. PMID: 34672133 Free PMC article.
Association between anti-TNF-α therapy and all-cause mortality.
Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. Herrinton LJ, et al. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1311-20. doi: 10.1002/pds.3354. Epub 2012 Oct 15. Pharmacoepidemiol Drug Saf. 2012. PMID: 23065964 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information